Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

Archive, CME credit no longer available
Release Date: October 19, 2010
Expiration Date: October 20, 2011

This activity consists of audio and visual recording of 7 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• Describe the current potential of gene therapy for HIV eradication
• Describe current data on HIV treatment as prevention
• Design antiretroviral strategies that consider current data on initiating therapy
• Explain the key clinical concerns associated with bone disease and vitamin D deficiency in HIV-infected patients
• Screen HIV-infected patients for non-AIDS-related malignancies
• Formulate appropriate management strategies for HIV and viral coinfections
  

CME Credit

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The International AIDS Society–USA designates this educational activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Course Faculty

Chairs

Roy M. Gulick, MD, MPH
Course Chair
Member, Board of Directors (Volunteer)
International AIDS SocietyUSA
Professor of Medicine
Chief, Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York

Judith A. Aberg, MD
Course Vice-Chair
Professor of Medicine
New York University Medical Center
Director of Virology
Director, AIDS Clinical Trials Unit
Bellevue Hospital Center
New York, New York

Speakers

Jessica E. Justman, MD
Associate Professor of Clinical Medicine in Epidemiology
Columbia University
New York, New York

Susan L. Koletar, MD
Professor of Internal Medicine
The Ohio State University
Columbus, Ohio

Thomas C. Quinn, MD
Professor of Medicine, International Health, Molecular Microbiology
and Immunology
The Johns Hopkins University
Baltimore, Maryland

Pablo Tebas, MD
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Michael T. Yin, MD
Assistant Professor of Clinical Medicine
Columbia University
New York, New York

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on scientific advisory boards for GlaxoSmithKline, ViiV Healthcare, and Merck & Co, Inc, and has chaired a data and safety monitoring board for Achillion Pharmaceuticals, Inc. (Updated 08/09/10)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc, and Schering-Plough Corp. (Updated 08/11/10)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp, and Sanofi Pasteur. (Updated 08/10/10)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to Abbott Laboratories. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. He has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, and ViiV Healthcare. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc, for research conducted by Dr Gallant. (Updated 08/10/10)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, MedImmune, LLC, ViiV Healthcare, and ViroStatics and as an investigator for research study grants (to Weill Cornell) from Pfizer Inc, Schering-Plough Corp, Tibotec Therapeutics, and Wyeth. (Updated 09/22/10)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 09/27/10)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated 08/09/10)

Michael S. Saag, MD
Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pain Therapeutics, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 08/10/10)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Achillion Pharmaceuticals, Inc, Gilead Sciences, Inc, Inhibitex, Inc, Johnson & Johnson Services, Inc, Tobira Therapeutics, and Laboratory Corporation of America. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 08/10/10)

Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc, and TaiMed Biologics, and on an endpoint adjudication committee for Schering-Plough Corp. He has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Pfizer Inc, and Tobira Therapeutics. (Updated 08/10/10)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Aberg has received grants and research support from Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec Therapeutics. She has served as a scientific advisor for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Theratechnologies Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 09/25/10)

Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, MedImmune, LLC, ViiV Healthcare, and ViroStatics and as an investigator for research study grants (to Weill Cornell) from Pfizer Inc, Schering-Plough Corp, Tibotec Therapeutics, and Wyeth. (Updated 09/22/10)

Dr Justman has no relevant financial affiliations to disclose. (Updated 09/11/10)

Dr Koletar has served as an investigator for studies sponsored by GlaxoSmithKline and Tibotec Therapeutics. (Updated 09/27/10)

Dr Quinn has no relevant financial affiliations to disclose. (Updated 09/22/10)

Dr Tebas has served as a consultant to Bristol-Myers Squibb, Merck & Co, Inc, and Pfizer Inc. (Updated 09/23/10)

Dr Yin has received grants and research support from Bristol-Myers Squibb and has served as a scientific advisor to Gilead Sciences, Inc. (Updated 09/22/10)


IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose (see above).

Ms Balderas has no relevant financial affiliations to disclose. (Updated 09/27/10)


Grant Support

This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.

Funding for the live activity, upon which this activity was based came from the following commercial companies:

Substantial Grants from:
Merck & Co, Inc
Tibotec Therapeutics

Bristol-Myers Squibb
Gilead Sciences, Inc

Generous Grants from:
ViiV Healthcare


Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org

I have read these instructions and understand them.